Advertisement cover the XIX International AIDS Conference (AIDS 2012)

AIDS 2012 Daily Digest: Division of HIV/AIDS Prevention Science

July 25, 2012

This digest summarizes the Division of HIV/AIDS Prevention science presented on Wednesday, July 25.

Participant Adherence in the Bangkok Tenofovir Study, an HIV Pre-Exposure Prophylaxis Trial in Bangkok

Lead Author: Michael Martin

Findings: Fifty-three percent met the criteria for adherence (taking the study drug at least 5 of 7 days/week with no more than two consecutive days off) and 41 percent reported taking the study drug every day. More than three-fourths (75%) of participants chose directly observed taking (DOT) during the entire 12 weeks, of which 58 percent met the adherence criteria and 46 percent took the study drug every day. Authors conclude that the Bangkok Tenofovir Study will be able to provide reliable adherence data to determine if tenofovir prevents HIV infection among intravenous drug users (IDUs).

Relevance: Participant adherence among IDUs enrolled in the Bangkok Tenofovir Study was assessed. Participants could choose either follow-up daily with DOT or study drug or monthly with DOT. Participants could change their decision during the trial period. Over 2,400 IDUs enrolled in the study. Adherence was measured based on participants' study drug diaries and pill counts.

Click here for more information.


Early HIV Infection and Transmissions Averted by Early Diagnosis Among Men Who Have Sex With Men in the United States

Lead Author: Pragna Patel

Findings: 43,559 individuals were screened in Los Angeles from April 2006 to March 2008. 302 men who have sex with men (MSM) were diagnosed with HIV and 12 percent of whom had early HIV infection. In a multivariate analysis MSM with early HIV infection were less likely to be black and more likely to have a negative HIV test in the last three months as compared with MSMs with established infection. Early HIV diagnosis of these 37 MSM resulted in 4.2 transmissions averted. More frequent testing is needed to prevent ongoing transmission.

Relevance: This study examined risk factors associated with early HIV infection among men who have sex with men (MSM) and the contribution to transmission averted by identifying early HIV infection.

Click here for more information.

Reasons for Methamphetamine Use and Type of Drug-Use Administration and Associations With Sexual Risk Behavior by HIV-Status Among High-Risk MSM in the United States

Lead Author: Gordon Mansergh

Findings: For both HIV positive and HIV negative men, taking methamphetamine ("meth") to have "better sex" was a primary motivator (among ten possible motivators) associated with meth use. For both HIV positive and HIV negative men, meth use itself is consistently associated with sexual risk behavior, even when considering motivations for meth use. Programs to reduce meth-sex and sex risk should focus on (a) the issue (true or untrue) of meth use facilitating "better sex" and (b) addressing meth use directly, given its consistent association with sexual risk even when considering various meth-use motivations.

Relevance: This large study of HIV+ and HIV-, substance-using men who have sex with men (MSM) in Chicago, Los Angeles, New York City, and San Francisco (Project MIX) sought to better understand motivation and context for meth use during sex and its link to sexual risk behavior, in order to develop informed programs to reduce meth-sex risk among MSM.

Click here for more information.

This article was provided by U.S. Centers for Disease Control and Prevention. Visit the CDC's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.